Introducing Sucraid® – Your Premier Solution for CSID Treatment!
We proudly announce our latest offering, Sucraid® (Sacrosidase) ORAL SOLUTION, now exclusively available through Pharmamed distribution. Thanks to our direct partnership with the manufacturer QOL MEDICAL LLC, we can guarantee unmatched quality and accessibility for our customers.
Currently, Sucraid® (sacrosidase) Oral Solution stands as the definitive pharmaceutical solution for Congenital Sucrase-Isomaltase Deficiency (CSID) in both pediatric and adult patients. Serving as a tailored enzyme replacement therapy for genetically determined sucrase deficiency, a key aspect of CSID, Sucraid® facilitates the breakdown and absorption of sucrose (commonly known as table sugar) in the intestine, effectively easing the gastrointestinal symptoms linked with CSID. It’s worth noting that Sucraid® is now available in both multi-dose bottles and single-use containers. For additional information, please visit www.sucraid.com.
Sucraid® acts as an enzyme replacement therapy, offering a viable substitute for the sucrase enzyme in the small intestine, which is either deficient or dysfunctional in individuals with CSID.
“Sucraid®: An Effective Treatment for CSID”
*Congenital Sucrase-Isomaltase Deficiency (CSID) is also referred to as Genetic Sucrase-Isomaltase Deficiency (GSID).
QOL Medical stands as a specialized biopharmaceutical company steadfast in its commitment to enhancing clinical outcomes and overall well-being for individuals grappling with rare medical conditions. Founded in 2003 with an unwavering focus on patient-centricity, QOL Medical is dedicated to sourcing and bringing to market orphan and gastrointestinal medications tailored for underserved populations.
